Skin infections (topicals):

Indications for: LOTRISONE

Tinea pedis, t. cruris, t. corporis.

Clinical Trials:

In clinical trials of tinea corporis, tinea cruris, and tinea pedis, patients treated with Lotrisone cream showed a better clinical response at the first return visit than those treated with clotrimazole cream. In tinea corporis and tinea cruris, the patient returned 3–5 days after starting treatment, and in tinea pedis, after 1 week. Mycological cure rates observed in patients treated with Lotrisone cream were as good as, or better than, in those treated with clotrimazole cream. In these same clinical studies, patients treated with Lotrisone cream showed better clinical responses and mycological cure rates compared with those treated with betamethasone dipropionate cream.

Adult Dosage:

T. cruris, t. corporis: apply thin film twice daily for 1 week; max 2 weeks. T. pedis: apply sufficient amount twice daily for 2 weeks; max 4 weeks. Max 45g per week. Do not occlude.

Children Dosage:

<17yrs: not recommended.

LOTRISONE Warnings/Precautions:

Avoid eyes. Do not use for diaper dermatitis. Risk of HPA axis suppression with high-potency steroids, prolonged use, application to large surface area, use of occlusive dressings, altered skin barrier, liver failure, young age; discontinue gradually, or reduce dose or potency if occurs. Increased risk of posterior subcapsular cataracts and glaucoma; monitor for visual symptoms. Thinning skin. Reevaluate periodically. Pregnancy. Nursing mothers: avoid direct infant exposure.

LOTRISONE Classification:

Steroid + azole antifungal.

Adverse Reactions:

Rash, edema, secondary infections; HPA axis suppression (esp. in children), skin atrophy.



Drug Elimination:


Generic Drug Availability:


How Supplied:

Crm—15g, 45g